首页> 外国专利> Norgestimate use as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels

Norgestimate use as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels

机译:Norgestimate用作trpc3,trpc6和trpc7离子通道的选择性抑制剂

摘要

TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention, norgestimate is shown to selectively inhibit TRPC3, TRPC6 and TRPC7.
机译:TRPC离子通道是在人体组织中广泛表达的非选择性通道。这些通道涉及许多生理功能,并且是开发新药的假定目标。需要更好地了解细胞内外的TRPC离子通道。本发明提供了一种药理学工具化合物,由于其对TRPC亚家族的区分性抑制作用,其可以研究TRPC离子通道。在本发明中,显示norgestimate选择性抑制TRPC3,TRPC6和TRPC7。

著录项

  • 公开/公告号BRPI0818823A2

    专利类型

  • 公开/公告日2015-04-22

    原文格式PDF

  • 申请/专利权人 SANOFI-AVENTIS;

    申请/专利号BR2008PI18823

  • 申请日2008-10-14

  • 分类号A61K31/57;A61P9;A61P13/12;A61P29;G01N33/15;

  • 国家 BR

  • 入库时间 2022-08-21 15:16:06

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号